Development of a Protocol for Use of a Vascular Access Protective Device to Prevent Self-injection

TEST INSTRUCTIONS Read the article. The test for this nursing continuing professional development (NCPD) activity is to be taken online at www.nursingcenter.com/CE/AENJ. Tests can no longer be mailed or faxed. You’ll need to create an account (it’s free!) and log in to access My Planner before taking online tests. Your planner will keep track of all your Lippincott Professional Development online NCPD activities for you. There’s only one correct answer for each question. A passing score for this test is 8 correct answers. If you pass, you can print your certificate of earned contact hours and access the answer key. If you fail, you have the option of taking the test again at no additional cost. For questions, contact Lippincott Professional Development: 1-800-787-8985. Registration deadline is March 3, 2028. PROVIDER ACCREDITATION Lippincott Professional Development will award 2.0 contact hours and 0 pharmacology contact hours for this nursing continuing professional development activity. Lippincott Professional Development is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 2.0 contact hours. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia, Georgia, West Virginia, New Mexico, South Carolina, and Florida, CE Broker #50-1223. Your certificate is valid in all states. Payment: The registration fee for this test is $21.95. Disclosure statement: The authors receive licensing fees for the IV CareLock device from Traveler Medical. These relevant financial relationships have been mitigated through peer review. There are no other relevant financial relationships for the authors or planners. CE TEST QUESTIONS Learning Outcome: By the conclusion of this activity, a majority of the participants will demonstrate knowledge of a protocol aimed at reducing self-injection into vascular access devices in an emergency department setting by achieving a passing score on the posttest. Learning Objectives: After completing this continuing professional development activity, the participant will apply knowledge gained to: Describe the current context regarding self-injection into vascular access device (SIVAD) in the emergency department (ED) setting. Explain the development, invention, and implementation of the IV CareLock device in one ED. Since 2023, overdose deaths have decreased slightly. increased significantly. remained the same. According to 2024 data from the Drug Enforcement Agency, the most urgent drug threat is currently fentanyl. heroin. oxycodone. Due to stigma and discrimination, patients who inject drugs (PWID) are three times more likely to become violent against hospital staff. commit suicide while in the hospital. leave the hospital against medical advice. Between 2002 and 2012, the rate of serious infections among PWID doubled. tripled. quadrupled. What prompted the investigators to develop the IV CareLock device? increasing numbers of overdose patients brought into their ED by ambulance potential for violence due to increasing wait times, boarding, and overcrowding in the waiting room of their ED two fatal overdoses from self-injection of nonprescribed substances that occurred while being treated in their ED When the investigators sought to ascertain the extent of SIVAD in the hospital setting, they discovered there was a paucity of data because practitioners were hesitant to discuss SIVAD. privacy laws prevented disclosure. reporting is not mandatory. Compared with other devices available to mitigate SIVAD, the IV CareLock device is the only one that both permits repeat access and is keyless. prevents patient access and allows infusion therapy. remains sterile and is magnetic resonance imaging compatible. According to the protocol developed for managing patients in the ED at risk for SIVAD, any team member could assess for risk factors and place the IV CareLock device. any team member could assess for risk factors and then obtain a practitioner order for the IV CareLock device. the practitioner was required to assess for risk factors and order the IV CareLock device. During the initial implementation of the IV CareLock device in the ED, what was identified as a challenge? patient resistance to device placement problems accessing the keys to the device significant device malfunction After the first month of implementation, the protocol was revised to require IV CareLock device placement in the waiting room only if patients had a history of leaving AMA. for patients deemed at high risk for SIVAD. when wait times exceeded 10 minutes.